No­var­tis li­cens­es two car­dio­vas­cu­lar RNAi drugs from Chi­nese biotech for $185M up­front

No­var­tis has inked a pair of li­cense and col­lab­o­ra­tion deals with RNA-fo­cused biotech Shang­hai Ar­go Bio­phar­ma­ceu­ti­cal for two car­dio­vas­cu­lar drugs, in a trans­ac­tion worth …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER